The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives

Trastuzumab was the first targeted therapy for HER2 positive breast cancer. It has become the standard of care for HER2 positive metastatic breast cancer since 2000 and in the adjuvant setting since 2006. Adjuvant it is given for a year and in patients with metastatic disease until progression. The...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Facts Views Vis Obgyn
Hlavní autoři: Papadmitriou, K., Trinh, X.B., Altintas, S., Van Dam, P.A., Huizing, M.T., Tjalma, W.A.A.
Médium: Artigo
Jazyk:Inglês
Vydáno: Universa Press 2015
Témata:
Perspective
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4788333/
https://ncbi.nlm.nih.gov/pubmed/26977267
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky